feed,title,long_url,short_url
BioRxiv,SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses,https://biorxiv.org/cgi/content/short/2021.12.21.473679v1?rss=1,https://j.mp/3qjjsKp
BioRxiv,"SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster",https://biorxiv.org/cgi/content/short/2021.12.22.473880v1?rss=1,https://j.mp/3yWrL2x
BioRxiv,Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant,https://biorxiv.org/cgi/content/short/2021.12.22.473804v1?rss=1,https://j.mp/3enr8FG
BioRxiv,Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice,https://biorxiv.org/cgi/content/short/2021.12.22.473914v1?rss=1,https://j.mp/3ekJ3gf
BioRxiv,Broad and Long-lasting Immune Response against SARS-CoV-2 Omicron and Other Variants by PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine (YS-SC2-010),https://biorxiv.org/cgi/content/short/2021.12.22.473615v1?rss=1,https://j.mp/3JrwKgL
BioRxiv,Waning immune responses against SARS-CoV-2 among vaccinees in Hong Kong,https://biorxiv.org/cgi/content/short/2021.12.22.473934v1?rss=1,https://j.mp/3H8Beql
